Here are some U.S. stocks under $10 that show great potential:
1. BlackSky Technology (BKSY): Specializing in geospatial intelligence, BlackSky has been securing significant contracts and has a bullish outlook among analysts. Currently priced around $1.10, it has a price target of $3.17, indicating substantial upside potential [[❞]](https://markets.businessinsider.com/news/stocks/7-cheap-stocks-under-10-with-10x-potential-july-2024-1033617331).
2. Mynaric (MYNA): This company develops laser communication technologies for aerospace and defense. With expected revenue growth and significant contracts, Mynaric is positioned for long-term gains, despite near-term profitability challenges [[❞]](https://markets.businessinsider.com/news/stocks/7-cheap-stocks-under-10-with-10x-potential-july-2024-1033617331).
3. Archer Aviation (ACHR): Focused on electric vertical takeoff and landing (eVTOL) aircraft, Archer has strong cash reserves and a promising future in the urban air mobility market. It’s trading around $3.50, with potential for significant growth if it can execute its plans [[❞]](https://investorplace.com/2024/07/7-dirt-cheap-stocks-under-10-with-explosive-upside-potential/).
4. Vimeo (VMEO): Known for its video hosting services, Vimeo has shown impressive financial results and profitability improvements. Priced under $5, analysts see strong future earnings growth and potential acquisition interest [[❞]](https://investorplace.com/2024/07/7-dirt-cheap-stocks-under-10-with-explosive-upside-potential/).
5. Genius Sports (GENI): Providing data and technology to sports and betting industries, Genius Sports has demonstrated strong revenue growth and is expected to continue expanding. Trading under $10, it offers substantial long-term potential [[❞]](https://investorplace.com/2024/07/7-dirt-cheap-stocks-under-10-with-explosive-upside-potential/).
These stocks come with risks, particularly in terms of volatility and profitability timelines, but they also offer significant growth potential for investors willing to take on some risk.
No reviews yet.